Borehamwood, 15th July 2014 – Pharmarama International Ltd announces its partnership with Nalpharm in an exclusive arrangement to administer a Managed Access Program (MAP) for its Naltrexone Implant “NalPlant”.
Pharmarama will immediately exclusively supply the NalPlant implant as part of a programme of treatment for substance abuse, via this MAP, to over 40 countries worldwide.
Naltrexone is an established drug used to aid addiction recovery by blocking the effects of opioids and alcohol. It is a non-addictive drug with limited side effects and has been shown to significantly increase the number of patients that remain in treatment programmes. The NalPlant implant is designed to release the Naltrexone drug consistently over a 12 week period. Healthcare professionals are able to access the drug for individual patients who are actively seeking rehabilitation for addiction via this MAP.
The Managed Access Program is an approved and...